Pancreatic Cancer Research

ResearcherUniversity of HelsinkiActive in the last 2 years

Caj H. Haglund

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0456-4965; OpenAlex author ID A5055369999, A5072327391, A5110119449. Sources: OpenAlex.

Their work

Papers
45 (first author 2, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
52
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: 4 papers · 2019: 1 paper · 2020: 4 papers · 2021: 5 papers · 2022: 10 papers · 2023: 2 papers · 2024: 5 papers · 2025: 2 papers · 2026: 5 papers

Papers 45

  1. Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19-9 as a Tool for Prognostic Evaluation in Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.71954↗
  2. Low Hepsin Expression Associates with a Better Response to Gemcitabine-Based Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000547820↗
  3. Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20191-5↗
  4. ASO Visual Abstract: Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20304-0↗
  5. ASO Author Reflections: Understanding the Prognostic Role of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20312-0↗
  6. The prognostic significance of MMP-8 tissue Immunoexpression in pancreatic ductal adenocarcinoma after neoadjuvant therapy. Co-author DOI 10.1038/s41598-025-10538-5↗
  7. Homeobox protein B6 and homeobox protein B8 control immune-cancer cell interactions in pancreatic cancer. Co-author DOI 10.1186/s43556-025-00292-5↗
  8. Venous thromboembolism incidence and association with overall survival in pancreatic cancer: A Finnish nationwide cohort study. Co-author DOI 10.1002/cam4.70014↗
  9. E2F transcription factors promote tumorigenicity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.7187↗
  10. The Prognostic Significance of Collagen VI in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002360↗
  11. Surveillance after resection of pancreatic ductal adenocarcinoma: How to do it and what are the benefits? Last author DOI 10.1177/14574969231156353↗
  12. Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival in Pancreatic Cancer. Co-author DOI 10.1245/s10434-023-14793-6↗
  13. Serum cytokine profiles in patients with pancreatic cancer and chronic pancreatitis. Co-author DOI 10.1016/j.pan.2023.07.004↗
  14. The possible dual role of Ang-2 in the prognosis of pancreatic cancer. Co-author DOI 10.1038/s41598-023-45194-0↗
  15. Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer. Co-author DOI 10.1002/cam4.4397↗
  16. Pancreatic cancer survival prediction via inflammatory serum markers. Last author DOI 10.1007/s00262-021-03137-6↗
  17. Use of self-expandable metallic stents for endoscopic biliary decompression decreases stent complications in pancreatic cancer patients receiving chemotherapy. Co-author DOI 10.1007/s00464-021-08327-y↗
  18. Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer patients. Co-author DOI 10.1016/j.ejso.2021.11.116↗
  19. Pancreatic cancer - the past, the present, and the future. First author DOI 10.1080/00365521.2022.2067786↗
  20. Lipid Metabolic Reprogramming Extends beyond Histologic Tumor Demarcations in Operable Human Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-0396↗
  21. Pancreatic fibrosis, acinar atrophy and chronic inflammation in surgical specimens associated with survival in patients with resectable pancreatic ductal adeno… Co-author DOI 10.1186/s12885-021-09080-0↗
  22. The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvant therapy. Last author DOI 10.1371/journal.pone.0267792↗
  23. β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancer. Co-author DOI 10.3233/tub-211581↗
  24. Matrix Metalloproteinase 8 Expression in a Tumour Predicts a Favourable Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms23063314↗
  25. Levels of the cancer biomarker CA 19-9 are associated with thrombin generation in plasma from treatment-naïve pancreatic cancer patients. Co-author DOI 10.1016/j.thromres.2020.12.018↗
  26. Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-020-80778-0↗
  27. Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer. Co-author DOI 10.1038/s41598-021-89134-2↗
  28. TKTL1 as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma and Its Correlation with FDG-PET-CT. Last author DOI 10.1159/000510862↗
  29. Changes in CRP and CA19-9 during Preoperative Oncological Therapy Predict Postoperative Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000517835↗
  30. Association between chronic pancreatitis and pancreatic cancer: A 10-year retrospective study of endoscopically treated and surgical patients. Co-author DOI 10.1002/ijc.32971↗
  31. Proteostasis Dysregulation in Pancreatic Cancer. First author DOI 10.1007/978-3-030-38266-7_4↗
  32. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1920240117↗
  33. Label-free proteomics reveals serum proteins whose levels differ between pancreatic ductal adenocarcinoma patients with short or long survival. Last author DOI 10.1177/1010428320936410↗
  34. Toll-like receptor 1 predicts favorable prognosis in pancreatic cancer. Last author DOI 10.1371/journal.pone.0219245↗
  35. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer. Co-author DOI 10.1080/0284186x.2017.1415458↗
  36. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma. Last author DOI 10.1177/1010428318761494↗
  37. Toll-like receptor 2 and Toll-like receptor 4 predict favorable prognosis in local pancreatic cancer. Last author DOI 10.1177/1010428318801188↗
  38. Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/1076029618779133↗
  39. Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis. Co-author DOI 10.1002/cam4.1107↗
  40. Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/1010428317710411↗
  41. The Results of Pancreatic Resections and Long-Term Survival for Pancreatic Ductal Adenocarcinoma: A Single-Institution Experience. Co-author DOI 10.1177/1457496916645963↗
  42. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12885-016-2497-5↗
  43. Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1371/journal.pone.0163064↗
  44. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1371/journal.pone.0129012↗
  45. Comparison of sialylated N-glycopeptide levels in serum of pancreatic cancer patients, acute pancreatitis patients, and healthy controls. Co-author DOI 10.1002/pmic.201300270↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hanna E. Seppänen · 41 shared papers, 2015–2026 · strength 6.96
  2. Malin Sund · 7 shared papers, 2022–2026 · strength 1.74
  3. Anna Maria Nurmi · 8 shared papers, 2018–2024 · strength 1.37
  4. Ella Kesti · 5 shared papers, 2024–2026 · strength 1.25
  5. Riitta Lassila · 5 shared papers, 2018–2026 · strength 1.03
  6. Nora Mattila · 4 shared papers, 2018–2026 · strength 0.80
  7. Jun Yoshino · 3 shared papers, 2026 · strength 0.77
  8. Nils O. Elander · 3 shared papers, 2026 · strength 0.77
  9. Asif Halimi · 3 shared papers, 2026 · strength 0.77
  10. Oskar Franklin · 3 shared papers, 2026 · strength 0.77
  11. Hakon Blomstrand · 3 shared papers, 2026 · strength 0.77
  12. Daniel Öhlund · 3 shared papers, 2026 · strength 0.77
  13. Annika Eurola · 4 shared papers, 2021–2025 · strength 0.74
  14. Leena Kylänpää · 4 shared papers, 2020–2024 · strength 0.69
  15. Mira Lanki · 4 shared papers, 2018–2023 · strength 0.60
  16. Pauli Antero Puolakkainen · 4 shared papers, 2016–2024 · strength 0.59
  17. Roland E. Andersson · 2 shared papers, 2022–2024 · strength 0.59
  18. Daniel Ansari · 2 shared papers, 2022–2024 · strength 0.59
  19. Olli Carpén · 3 shared papers, 2018–2024 · strength 0.49
  20. Isabella Artner · 2 shared papers, 2024–2025 · strength 0.43
  21. Ludivine Bertonnier‐Brouty · 2 shared papers, 2024–2025 · strength 0.43
  22. Kapo Saukkonen · 5 shared papers, 2015–2021 · strength 0.42
  23. Mirjami Kaasinen · 2 shared papers, 2022–2025 · strength 0.42
  24. Panu Aaltonen · 2 shared papers, 2022–2024 · strength 0.40
  25. Sini Vehviläinen · 2 shared papers, 2022–2024 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.